Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1895 2
1915 1
1947 1
1948 1
1949 3
1955 1
1959 1
1960 1
1964 3
1966 1
1967 5
1968 3
1969 2
1970 7
1971 1
1972 3
1973 2
1974 1
1975 6
1976 8
1977 6
1978 3
1979 9
1980 6
1981 3
1982 2
1983 4
1984 9
1985 11
1986 12
1987 15
1988 8
1989 9
1990 18
1991 17
1992 12
1993 16
1994 19
1995 24
1996 19
1997 24
1998 31
1999 26
2000 48
2001 32
2002 27
2003 34
2004 29
2005 42
2006 48
2007 46
2008 63
2009 71
2010 69
2011 69
2012 86
2013 100
2014 93
2015 115
2016 117
2017 102
2018 112
2019 102
2020 116
2021 145
2022 144
2023 106
2024 98
2025 129
2026 47

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,265 results

Results by year

Filters applied: . Clear all
Page 1
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, Seligmann J, De Baere T, Osterlund P, Yoshino T, Martinelli E; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Cervantes A, et al. Among authors: arnold d. Ann Oncol. 2023 Jan;34(1):10-32. doi: 10.1016/j.annonc.2022.10.003. Epub 2022 Oct 25. Ann Oncol. 2023. PMID: 36307056 Free article. No abstract available.
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.
Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, García-Alfonso P, Kocsis J, Cubillo Gracian A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Paulson AS, Masuishi T, Jones J, Csőszi T, Cremolini C, Ghiringhelli F, Shergill A, Hochster HS, Krauss J, Bassam A, Ducreux M, Elme A, Faugeras L, Kasper S, Van Cutsem E, Arnold D, Nanda S, Yang Z, Schelman WR, Kania M, Tabernero J, Eng C; FRESCO-2 Study Investigators. Dasari A, et al. Among authors: arnold d. Lancet. 2023 Jul 1;402(10395):41-53. doi: 10.1016/S0140-6736(23)00772-9. Epub 2023 Jun 15. Lancet. 2023. PMID: 37331369 Clinical Trial.
How patients with multiple sclerosis acquire disability.
Lublin FD, Häring DA, Ganjgahi H, Ocampo A, Hatami F, Čuklina J, Aarden P, Dahlke F, Arnold DL, Wiendl H, Chitnis T, Nichols TE, Kieseier BC, Bermel RA. Lublin FD, et al. Among authors: arnold dl. Brain. 2022 Sep 14;145(9):3147-3161. doi: 10.1093/brain/awac016. Brain. 2022. PMID: 35104840 Free PMC article.
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon DA, Massard C, Minchom A, Lugowska I, Carranza O, Arnold D, Gutierrez M, Winter H, Stuyckens K, Crow L, Najmi S, Hammond C, Thomas S, Santiago-Walker A, Triantos S, Sweiti H, Loriot Y; RAGNAR Investigators. Pant S, et al. Among authors: arnold d. Lancet Oncol. 2023 Aug;24(8):925-935. doi: 10.1016/S1470-2045(23)00275-9. Lancet Oncol. 2023. PMID: 37541273 Free PMC article. Clinical Trial.
Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis.
Oh J, Arnold DL, Cree BAC, Ionete C, Kim HJ, Sormani MP, Syed S, Chen Y, Maxwell CR, Benoit P, Turner TJ, Wallstroem E, Wiendl H; Tolebrutinib Phase 3 GEMINI 1 and 2 Trial Group. Oh J, et al. Among authors: arnold dl. N Engl J Med. 2025 May 15;392(19):1893-1904. doi: 10.1056/NEJMoa2415985. Epub 2025 Apr 8. N Engl J Med. 2025. PMID: 40202623 Clinical Trial.
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Kindler HL, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, Bordia S, McGuinness D, Cui K, Locker GY, Golan T. Kindler HL, et al. Among authors: arnold d. J Clin Oncol. 2022 Dec 1;40(34):3929-3939. doi: 10.1200/JCO.21.01604. Epub 2022 Jul 14. J Clin Oncol. 2022. PMID: 35834777 Free PMC article. Clinical Trial.
VITT-like Monoclonal Gammopathy of Thrombotic Significance.
Wang JJ, Warkentin TE, Schönborn L, Wheeler MB, Geerts WH, Costedoat-Chalumeau N, Gendron N, Ene G, Lozano M, Langer F, Lindhoff-Last E, Budde K, Chataway T, Troelnikov A, Sheppard JI, Zhang Y, Arnold DM, Gordon TP, Thiele T, Greinacher A, Nazy I. Wang JJ, et al. Among authors: arnold dm. N Engl J Med. 2025 Mar 6;392(10):995-1005. doi: 10.1056/NEJMoa2415930. Epub 2025 Feb 12. N Engl J Med. 2025. PMID: 39938091
AI-driven reclassification of multiple sclerosis progression.
Ganjgahi H, Häring DA, Aarden P, Graham G, Sun Y, Gardiner S, Su W, Berge C, Bischof A, Fisher E, Gaetano L, Thoma SP, Kieseier BC, Nichols TE, Thompson AJ, Montalban X, Lublin FD, Kappos L, Arnold DL, Bermel RA, Wiendl H, Holmes CC. Ganjgahi H, et al. Among authors: arnold dl. Nat Med. 2025 Oct;31(10):3414-3424. doi: 10.1038/s41591-025-03901-6. Epub 2025 Aug 20. Nat Med. 2025. PMID: 40835969 Free PMC article.
2,265 results